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Background: Molecular alterations are well studied in colon cancer, however there is still need for an improved
understanding of their prognostic impact. This study aims to characterize colon cancer with regard to KRAS, BRAF,
and PIK3CA mutations, microsatellite instability (MSI), and average DNA copy number, in connection with tumour
dissemination and recurrence in patients with colon cancer.
Methods: Disease stage II-IV colon cancer patients (n = 121) were selected. KRAS, BRAF, and PIK3CA mutation
status was assessed by pyrosequencing and MSI was determined by analysis of mononucleotide repeat markers.
Genome-wide average DNA copy number and allelic imbalance was evaluated by SNP array analysis.
Results: Patients with mutated KRAS were more likely to experience disease dissemination (OR 2.75; 95% CI
1.28-6.04), whereas the opposite was observed for patients with BRAF mutation (OR 0.34; 95% 0.14-0.81) or MSI
(OR 0.24; 95% 0.09-0.64). Also in the subset of patients with stage II-III disease, both MSI (OR 0.29; 95% 0.10-0.86)
and BRAF mutation (OR 0.32; 95% 0.16-0.91) were related to lower risk of distant recurrence. However, average
DNA copy number and PIK3CA mutations were not associated with disease dissemination.
Conclusions: The present study revealed that tumour dissemination is less likely to occur in colon cancer patients
with MSI and BRAF mutation, whereas the presence of a KRAS mutation increases the likelihood of disseminated
disease.
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Colorectal cancer (CRC) is the third most common can-
cer and the second most common cause of cancer-
related death in Sweden [1]. Metastatic disease is present
at diagnosis in 20-25% of patients and another 20-25%
develops metastases in the course of the follow-up time.
As local disease nowadays rarely is a cause of death in
cancer of the colon and rectum [2], tumour cell dissem-
ination may be considered a prerequisite for tumour
death. To be able to improve survival by more appropri-
ate treatment selection in primary disease, focus must
therefore be on the identification of tumours with the* Correspondence: helgi.birgisson@surgsci.uu.se
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unless otherwise stated.capability to disseminate, whether clinically apparent at
diagnosis (stage IV) or detected during follow-up after
curative surgery (stages II and III).
The TNM (tumour-node-metastasis) classification
based on radiologic and histopathological evaluation is
currently the most reliable method for treatment selec-
tion and prognostic prediction in patients with CRC [3].
Patients curatively operated for stage II disease have
around 15% risk of developing disease recurrence [4] if
staged appropriately, operated according to modern
principles and assessed with high quality pathology. Due
to low risk of recurrence, these patients are regularly not
given adjuvant chemotherapy, unless they are considered
to be at “high risk” due to poor prognostic features such
as T4, emergency operation or vascular invasion [5,6].
Patients with stage III disease have approximately a 40%al. This is an Open Access article distributed under the terms of the Creative
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5-fluorouracil (5-FU)/leucovorin in patients with stage
III disease reduces this risk by approximately 30%. If
5-FU/leucovorin is combined with oxaliplatin, the re-
currence rate is further decreased with 15-20% [7].
Obviously, a subgroup of patients with stage III disease is
given adjuvant chemotherapy with limited survival bene-
fits. At the same time, there is an under-treatment of the
subset of stage II patients that eventually develop recur-
rent disease.
CRC is heterogeneous with regard to molecular alter-
ations and characterization of the molecular aetiology of
sporadic CRC has identified different oncogenic path-
ways. The two major genomic instability pathways are
the “traditional” chromosomal instability (CIN), or aneu-
ploidy pathway, and the microsatellite instability (MSI)
pathway [8-11]. These two pathways have been de-
scribed as mutually exclusive, as the CIN tumours are
microsatellite stable (MSS) [12]. CIN positive tumours
constitute 65-70% of CRCs and have been associated
with an aggressive clinical behaviour and distal location
[10,13]. Tumours with CIN usually have large genomic
aberrations that lead to higher average DNA copy num-
ber compared with MSI tumours [14]. Absolute DNA
copy numbers can be assayed by SNP arrays and subse-
quent allele-specific analysis [15]. The MSI phenotype is
the result of gene silencing of DNA mismatch repair
(MMR) genes that cause accumulation of mutations
in tumour suppressor genes and oncogenes. The MSI
phenotype is therefore also referred to as the MMR
deficient or mutator phenotype. CRC with MSI ac-
counts for approximately 15% of sporadic CRCs and is
characterized by a more proximal location, mucinous
differentiation, near-diploid chromosome set and better
prognosis compared to MMR proficient, frequently CIN
positive, CRC [16-19]. Some CRC tumours also display
epigenetic instability manifested as CpG island methyla-
tor phenotype (CIMP) or global DNA hypomethylation.
CIMP-positive tumours are strongly associated with the
MSI phenotype and the presence of BRAF mutations
[20,21]. An additional CRC subtype comprises MSS CIN
negative (diploid) tumours that also frequently are CIMP
positive and BRAF mutated [12].
CRC tumourigenesis is also dependent on mutations
in genes that deregulate intracellular signaling pathways,
e.g. the EGFR mitogen-activated protein kinase (MAPK)
and phosphatidylinositol 3-kinase (PI3K) pathways. Fre-
quently mutated genes in these pathways are KRAS,
BRAF and PIK3CA. Similar to CIN and MSI, these genes
have been suggested as prognostic biomarkers, but al-
though examined in many previous studies, the precise
prognostic role of mutations in these genes remains
unclear [22,23]. Based on the increased molecular know-
ledge of CRC, a classification of sporadic CRC into fivedifferent entities has been proposed [12]. However, the
clinical value of these entities is still unclear and con-
flicting data exists among studies, probably a result of
the heterogeneity of CRC resulting in overlap between
the different pathways involved in CRC tumourigenesis.
In order to better understand tumour cell characteris-
tics in primary colon cancers associated with tumour cell
dissemination, and disease recurrence, the aim of this
study was to characterize colon tumours, stratified by
tumour stage and presence or development of metastatic
disease, with regard to KRAS, BRAF, and PIK3CA muta-
tions, MSI, and average DNA copy number.
Methods
Patient material and study design
Fresh frozen tumour material was available for molecu-
lar analysis from over 600 patients with primary colon
and rectal cancer operated at the Uppsala University
Hospital, Sweden, between 1987 and 2006, or at the
Central District Hospital in Västerås, Sweden, between
2000 and 2003. From this population patients with stage
II and III tumours, with and without recurrent disease,
and patients with stage IV disease at diagnosis, were
identified. To enable comparisons of tumours with and
without metastatic capability, patients with synchronous
metastases at diagnosis were considered equivalent to
those with metastases appearing during the follow-up
period, as both synchronous and metachronous metasta-
ses develop from the primary tumour and may indicate
the presence of certain traits. The terms “non-dissemi-
nated” was used for patients with stage II and III tu-
mours without recurrence and “disseminated” for stages
II and III with recurrence together with stage IV.
Only colon cancers were selected as rectal cancers
are often treated preoperatively with radiation and/or
chemotherapy and rectal cancer can differ from colon
cancer in the mutation profile. To ensure the high
quality of the study population, only radiologically ad-
equately staged patients and those operated abdominally
according to either right-sided or left-sided hemicolect-
omy or sigmoidectomy were included. No preoperative
therapy was allowed and the surgery was required to be
radical (R0). Patients with stage II disease were only in-
cluded if at least 10 lymph nodes were analyzed. More-
over, patients with stages II-III, with no disease recurrence
were only included if the follow-up time was longer than
5 years.
Haematoxylin-eosin stained tissue sections were pre-
pared from OCT-embedded fresh-frozen specimens
using a cryostat and the CryoJane tape-transfer system
(Instrumedics, Richmond, IL). The tumour tissue sections
were examined by a trained pathologist to ensure that
only representative samples containing more than 40%
tumour cells were included.
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from 121 patients was selected for analysis; 25 with dis-
ease stage II and 28 with stage III without disease recur-
rence; 15 with stage II and 27 with stage III with distant
recurrence and 26 with stage IV disease. Totally 68 pa-
tients were therefore regarded as disseminated and 53 as
non-disseminated. The stage II group with disease recur-
rence had to be limited to 15 cases as no more eligible
patients could be identified; otherwise the aim was to
include at least 25 patients in each group. Basic clinical
and histopathological information of the selected cohort
is given in Additional file 1: Table S1.
DNA extraction
Genomic DNA was extracted from 5-10 frozen tissue
sections (10 μm) using the QIAamp DNA Mini Kit
(Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s recommendations. The purityand concen-
tration of the extracted DNA was assessed using a Nano-
Drop instrument (Thermo Scientific, Wilmington, DE).
Pyrosequencing
The PyroMark Q24 BRAF and KRAS v2.0 assays (Qiagen)
were used to detect mutations in BRAF (codon 600) and
KRAS (codons 12, 13 and 61 in exons 2 and 3) according
to the manufacturer’s recommendations. Novel pyrose-
quencing assays were developed for the analysis of known
PIK3CA mutation hotspots in exon 9 (codons 542, 545,
and 546) and exon 20 (codons 1043 and 1047). PCR
primers and sequencing primers were designed using the
PyroMark Assay Design 2.0 software (Qiagen). Forward
(F) and reverse (R) PCR primers and sequencing primers
(S) for PIK3CA were as follows (5’-3’): 9-F CAGCTC
AAAGCAATTTCTACACG (biotin); 9-R CTCCATTTT
AGCACTTACCTGTGAC; 9-S TG ACTCCATAGAAAA
TCTTT; 20-F GCAAGAGGCTTTGGAGTATTTC (bio-
tin); 20-R AG ATCCAATCATTTTTGTTGTC; 20-S TTT
TGTTGTCCAGCC. Briefly, ten nanogram of genomic
DNA was used in 25 μl PCR reactions. Eight (PIK3CA) or
20 μl (BRAF and KRAS) of the PCR product was subse-
quently subjected to pyrosequencing using Streptavidin
Sepharose High Performance (GE Healthcare, Uppsala,
Sweden), PyroMark Gold Q96 reagents, PyroMark
Q24 1.0.9 software, and a Q24 instrument (QIAGEN).
All identified mutations were confirmed in a second
analysis.
MSI analysis
Determination of MSI status was performed using MSI
Analysis System, version 1.2 (Promega, Madison, WI)
with 6 ng genomic DNA and analysis of five mononucle-
otide repeat markers (BAT25, BAT26, NR-21, NR-24
and MONO-27). Analyses were performed on a 3130xl
genetic analyzer (Applied Biosystems, Foster City, CA).According to guidelines from a National Cancer Insti-
tute workshop in 1997, samples were denoted MSI-High
(MSI-H) if two or more of the five markers show in-
stability, MSI-Low (MSI-L) if only one marker shows
instability and microsatellite stable (MSS) if no markers
display instability. In this study, MSI-L and MSS was
grouped together in the interpretation of MSI data,
therefore MSI refers to MSI-H and MSS refers to both
MSS and MSI-L.SNP array analysis
Array experiments were performed according to the
standard protocols for AffymetrixGeneChip® Mapping
SNP 6.0 arrays (AffymetrixCytogenetics Copy Number
Assay User Guide (P/N 702607 Rev2.), Affymetrix Inc.,
Santa Clara, CA). Briefly, 500 ng total genomicDNA
was digested with a restriction enzyme (Nsp, Sty), li-
gated to an appropriate adapter for the enzyme, and
subjected to PCR amplification using a single primer.
After digestionwith DNase I, the PCR products were
labeled with a biotinylatednucleotide analogue using
terminal deoxynucleotidyltransferaseand hybridized to
the microarray. Hybridized probes were captured by
streptavidin-phycoerythrin conjugates using the Fluid-
ics Station 450 and the arrays were finally scanned
using the GeneChip® Scanner 3000 7G. Normalization
and segmentation of genomic data was performed using
BioDiscovery Nexus Copy Number 6.0 and the SNP
Rank Segmentation algorithm [24,25] with default set-
tings. Genome-wide average DNA copy number (ploidy)
and the proportion of the genome with allelic imbalance
were determined using Tumour Aberration Prediction
Suite (TAPS) [15]. Average DNA copy number was calcu-
lated as the mean copy number of all genomic segments,
weighted on segment length. Near diploid tumours were
defined to have average copy number <2.5 and aneu-
ploid tumours to have average copy number ≥2.5. SNP
array data is available at GEO with accession number:
(GSE62875).Statistical analyses
The Mann-Whitney U test was used in comparisons of
non-parametric two group parameters, the Kruskal-
Wallis test for multiple groups and the Chi-square test
for dichotomous response parameters and to test differ-
ences in proportions between groups. A two-sided Fisher’s
exact test was used instead of the Chi-square test when
fewer than 30 cases where analysed in total or less than
10 cases in each group. Spearman’s rho was used to calcu-
late the correlation coefficient (r). The odds ratio (OR)
and the 95% confidence intervals (CI) were calculated ac-
cording to Ahlbom et al. [26]. Differences were considered
statistically significant if p < 0.05.
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Results
Of the 121 tumours analysed, 48 (40%) had KRAS muta-
tions, the mutations where located in codon 12 (65%),
codon 13 (31%) and codon 61 (4%). BRAF mutations
were detected in 28 (23%) of the tumours and PIK3CA
mutations were seen in 22 (18%) tumours mainly in
exon 9 (n = 18; 82%) with 4 mutations in exon 20 (18%).
MSI-H was detected in 24 (20%) tumours and MSI-L in
7 (6%). DNA copy number <2.5 were seen in 66 out of
116 (57%) tumours analysed. In Table 1 the main clinicalTable 1 Clinical and histopathological relations of KRAS, BRA











Number 121 73 48 93 28 97
Age at diagnosis
Years (mean) 70 71 69 0,346 69 72 0,388 71
Gender
Female 71 43 28 0.950 51 20 0.132 57
Male 50 30 20 42 8 42
Tumour location
Right colon 73 43 30 0.692 49 24 0.002 56
Left colon 48 30 18 44 4 43
Tumour stage
Stage II 40 29 11 0,008 28 12 0,160 35
Stage III 55 34 21 43 12 45
Stage IV 26 10 16 22 4 19
Tumour size
<5 cm 38 22 16 0.749 31 7 0.639 31
≥5 cm 82 50 32 62 20 67
Missing data 1
Differentiation
Poor 28 20 8 0,193 18 10 0.072 18
Well-moderate 93 53 40 75 18 81
Mucinous
No 102 62 40 0,804 81 21 0.143 84
Yes 19 11 8 12 7 15
Perineural invasion
No 117 71 2 0.649 89 28 0.572 97
Yes 4 46 2 4 0 2
Vascular invasion
No 104 65 39 0,287 78 26 0.354 85
Yes 17 8 9 15 2 14
Wt: wildtype; mut: mutation.and histopathological characteristics of the cohort are
shown in relations to KRAS, BRAF and PIK3CA muta-
tions and MSI and DNA copy number. The main find-
ings were that KRAS mutation was associated with
advanced disease stage, BRAF mutations were mainly
found in right colon, PIK3CA was associated with poor
tumour differentiation, MSI was more commonly seen
in lower disease stage, larger and more poorly differen-
tiated tumours. However, DNA copy number did not
reveal any associations to the variables analysed (Table 1).
The well-known mutual exclusiveness of KRAS and
BRAF mutations was observed (Table 2 and Figure 1),
and MSI was more prevalent in KRAS wild-type and




p MSS MSI p DNA copy number p
<2.5 ≥2.5
22 97 24 66 50
67 0,380 70 70 0,858 71 69 0,412
14 0.641 54 17 0.177 37 31 0.520
8 43 7 29 19
17 0.093 55 18 0.110 39 31 0.751
5 42 6 27 19
5 0,147 27 13 0,010 26 14 0,247
10 46 9 28 25
7 24 2 12 11
7 0.100 36 2 0.011 21 16 0.972
15 61 21 44 34
10 0.006 14 14 <0.001 18 9 0.274
12 83 10 48 41
18 0.748 84 18 0.208 55 42 0.100
4 13 6 11 8
20 0.151 93 24 0.583 64 49 1.000
2 4 0 2 1
18 1.000 81 23 0.189 58 42 0.549
3 16 1 8 8
Table 2 Correlations between KRAS, BRAF and PIK3CA mutations, MSI (n = 121) and DNA copy number (n = 115) in
primary tumours from patients with colon cancer
BRAF PIK3CA MSI vs MSS DNA copy number
Mut Wt p r Mut Wt p r MSI MSS p r <2.5 ≥2.5 Missing p r
KRAS
Mutation 0 48 <0.001 -0.414 9 39 0.100 -0.003 2 46 <0.001 -0.338 22 22 3 0.169 -0.146
Wild type 28 45 13 60 22 51 46 25 3
BRAF
Mutation 10 18 0.006 -0.213 18 10 <0.001 0.657 23 5 0.009 0.265
Wild type 12 81 6 87 45 42 6
PIK3CA
Mutation 8 14 0.041 0.173 14 7 1 0.595 0.072
Wild type 16 83 54 40 5
MSI
MSI 23 0 1 <0.001 0.416
MSS 45 47 5
Wt: Wild type; Mut: Mutation; r: Correlation coefficient.
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ence of BRAF mutations and MSI (Table 2) and, in con-
trast to the mutual exclusive pattern of KRAS and BRAF
mutations, PIK3CA mutations coexisted with mutations
in the two other genes.Figure 1 Venn diagrams representing the interrelations of KRAS, BRA
with colon cancer; a) the entire cohort (n = 121); b) non-disseminatedTumours with average DNA copy number <2.5 fre-
quently exhibited MSI and mutated BRAF. None of the
tumours with MSI demonstrated an average DNA copy
number ≥2.5 (Table 2 and Figure 2). On the contrary, 51
percent of the MSS tumours demonstrated an averageF, PIK3CA mutations and MSI in primary tumours from patients
disease (n = 53) and c) disseminated disease (n = 68).
Figure 2 MSS/MSI-L and MSI-H samples were plotted according
to average DNA copy number and proportion of the genome
with allelic imbalance (%).
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panied by a high proportion of the genome affected by
allelic imbalance (Figure 2). However, average DNA copy
number was neither associated with KRAS, nor PIK3CA
mutation status (Table 2).
DNA copy number or PIK3CA mutations revealed no
associations with disseminated disease or recurrence in
the whole study cohort, or in various subgroup combi-
nations of the cohort, and were therefore excluded from
further analysis.
KRAS mutated tumours were more commonly seen in
patients with disseminated disease. In contrast, BRAF
mutations or MSI were less common in tumours from
patients with disseminated disease or in those develop-
ing recurrence in disease stages II and III (Table 3). No
statistically significant associations were seen when dis-
ease stages II and III were analysed separately (data not
shown).
Higher frequency of KRAS mutations was observed in
tumours from patients with higher disease stages; 28% in
stage II; 38% in stage III and 62% in stage IV. Whereas
mutated BRAF, as well as MSI, were more frequent in
lower disease stages; BRAF mutation frequency was 30%
in stage II; 22% in stage III and 15% in stage IV and the
frequency of MSI was: 33% in stage II; 16% in stage III
and 8% in stage IV. When these genotypes were analysed
separately in left and right colon, MSI and BRAF muta-
tions were observed more frequently in the right colon
and these molecular changes were present in both
tumours from patients with, or without, recurrence in
disease stages II and III and in disseminated disease(Table 4). For left colon, MSI and BRAF mutations could
not be found in tumours from patients developing dis-
ease recurrence in stages II or III and were rare in those
with disseminated disease (Table 4). On the contrary,
KRAS mutations had a stronger association with dissem-
inated disease in left compared with right colon (Table 4).
Overall KRAS was the most frequently mutated gene in
patients with disseminated disease (Figure 1c) and KRAS
codon 12 glycine to valine mutations was seen in 10 of
34 KRAS mutated tumours in patients with dissemi-
nated disease compared to 2 of 14 KRAS mutated tu-
mours in patients with non-disseminated disease (data
not shown).
In Table 3, patients with MSS tumours only, KRAS
wild type only and BRAF wild type only are also pre-
sented according to molecular status, dissemination and
recurrence. Among these subgroups, patients with
KRAS wild type tumours that are MSI are less likely
(p = 0.041) to have disseminated disease. Patients with
KRAS mutated MSS tumours appear more likely to
have disseminated disease, but recurrences in stages II
and III disease were not more frequent when MSS
tumours were KRAS mutated. The same trend for dissem-
ination can be seen for BRAF wild type tumours with a
KRAS mutation (Table 3). The OR for dissemination for
BRAF mutated tumours is low both in MSS tumours and
in KRAS wild type tumours; however these results are sta-
tistically non-significant.
In an attempt to identify specific subgroups of molecu-
lar markers that could help to detect patients with high
or low risk of disease dissemination, or recurrence in
stages II and III, several combinations of markers were
of interest. Patients with tumours presenting both KRAS
wild type and MSI had a reduced risk of dissemination
(OR 0.22; 95% CI 0.08-0.62) and recurrence in disease
stages II and III (OR 0.31; 95% CI 0.10-0.94) compared
with all other groups. On the other hand, patients with
tumours harbouring both BRAF wild type and MSS pre-
sented a higher risk of disseminated disease, and disease
recurrence in stages II and III compared with all other
groups (Table 3). Tumours with both BRAF mutation
and MSI had the lowest risk for dissemination also mar-
ginally significant for lower risk for disease recurrence in
stages II and III (Table 3). No statistically significant
differences were seen when stages II and III were ana-
lysed separately with aforementioned subgroups (data
not shown).
Discussion
The present study revealed that tumour dissemination is
less likely to occur in colon cancer patients with micro-
satellite instable (MSI) disease or mutated BRAF, as
compared to patients with MSS or BRAF wild-type tu-
mours. On the contrary, disseminated disease was more
Table 3 The associations of KRAS and BRAF mutations and MSI to the risk of recurrence and dissemination in patients
with colon cancer









n 42 53 68 53
KRAS
Mutation 18 14 2.09 (0.88-4.96) 0.092 34 14 2.75 (1.28-6.04) 0.009
Wild type 24 39 34 39
BRAF
Mutation 6 18 0.32 (0.16-0.91) 0.034 10 18 0.34 (0.14-0.81) 0.013
Wild type 36 35 58 35
MSI
MSI 5 17 0.29 (0.10-0.86) 0.027 7 17 0.24 (0.09-0.64) 0.005
MSS 37 36 61 36
MSS only
KRAS
Mutation 18 13 0.95 (0.35-2.58) 0.279 33 13 2.08 (0.89-4.86) 0.087
Wild type 19 23 28 23
BRAF
Mutation 2 5 0.35 (0.06-1.96) 0.261 5 5 0.55 (0.15-2.06) 0.492
Wild type 35 31 56 31
KRAS wild type only
MSI
MSI 5 16 0.38 (0.12-1.22) 0.168 6 16 0.31 (0.10-0.91) 0.041
MSS 19 23 28 23
BRAF
Mutation 6 18 0.39 (0.13-1.19) 0.115 10 18 0.49 (0.18-1.28) 0.142
Wild type 18 21 24 21
BRAF wild type only
MSI
MSI 1 4 0.22 (0.02-2.09) 0.198 2 4 0.28 (0.04-1.60) 0.194
MSS 35 31 56 31
KRAS
Mutation 18 14 1.50 (0.59-3.84) 0.397 34 14 2.13 (0.90-4.99) 0.082
Wild type 18 21 24 21
MSI and BRAF*
BRAF wild type + MSS 35 31 3.55 (1.33-9.44) 0.013 56 31 3.31 (1.45-7.59) 0.004
BRAF mutation + MSS 2 5 0.48 (0.09-2.61) 0.459 5 5 0.76 (0.21-2.78) 0.747
BRAF mutation + MSI 4 13 0.32 (0.10-1.08) 0,050 5 13 0.24 (0.08-0.74) 0.011
BRAF wild type + MSI 1 4 0.30 (0.03-2.78) 0.379 2 4 0.37 (0.07-2.11) 0.403
βNon-disseminated: Disease stages II and III without recurrence; ¥Disseminated: Disease stages II and III with recurrence and stage IV.
*The comparison of each subgroup is made with all other groups.
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compared to their KRAS wild-type counterparts.
This study is among the first that describes frequencies
of mutations and microsatellite instability in associationwith disease dissemination (metastatic disease either
present at the time of diagnosis or developed during
follow-up time) in a selected subset of colon cancer pa-
tients. The rationale behind including patients with stage
Table 4 The prognostic associations of KRAS mutation, BRAF mutation and MSI in right versus left colon in 121
patients with colon cancer
Diseasestage II and III All
Recurrence No recurrence Odds ratio (95%
Confidence interval)




MSI 5 12 0,40 (0,12-1,31) 0,158 6 12 0,31 (0,10-0,95) 0.055
MSS 22 21 34 21
Leftcolon
MSI 0 5 * 0,057 1 5 0,11 (0,01-1,04) 0.069
MSS 15 15 27 15
Rightcolon
BRAFmutation 6 14 0,38 (0,12-1,21) 0,168 10 14 0,45 (0,17-1,22) 0.138
BRAFwildtype 21 19 30 19
Leftcolon
BRAFmutation 0 4 * 0,119 0 4 0.025
BRAFwildtype 15 16 28 16 *
Rightcolon
BRAF/MSIpresent 7 16 0,37 (0,12-1,12) 0,110 11 16 0,40 (0,15-1,07) 0.089
BRAF/MSI absent 20 17 29 17
Leftcolon
BRAF/MSIpresent 0 6 * 0,024 1 6 0,09 (0,01-0,79) 0.015
BRAF/MSI absent 15 14 27 14
Rightcolon
KRASmutation 13 10 2,13 (0,74-6,16) 0,157 20 10 2,3 (0,87-6,05) 0.089
KRASwildtype 14 23 20 23
Leftcolon
KRASmutation 5 4 2,00 (0,43-9,27) 0,451 14 4 4,00 (1,07-15,01) 0.041
KRASwildtype 10 16 14 16
βNon-disseminated: Disease stage II and III without recurrence; ¥Disseminated: Disease stage II and III with recurrence and stage IV. *Not able to calculate OR
because of 0 in one grupp.
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metastatic disease, together with stage IV patients (meta-
static disease at diagnosis), was to facilitate the detection
of predictive genotypes in a cost-effective way. The ap-
plied unmatched case-control design enabled a smaller
number of samples to be analysed, while the number of
critical events was maintained. However, it should be
noted that the reduced sample size of each subgroup, as
a result of the applied selection criteria, also might limit
the power to detect statistically significant differences
between the subgroups. Furthermore, even based on a
large material of over 600 frozen tissue samples, we were
unable to include the planned number of stage II
patients with metastatic recurrence. The strict quality
requirements with regard to staging, surgery, and
pathology contributed to this inability, but at the same
time likely increased the validity of the results, as the in-
fluence of unrelated factors was minimised.The observed mutation frequencies in the present in-
vestigation should be interpreted with caution, as this
cohort is not population-based. Even so, the KRAS mu-
tation frequency of 40% in this cohort was in good
agreement with other published studies [27-29]. More-
over, we observed that the proportion of KRAS mutated
patients increased with higher disease stage, a finding
supported by Eklöf et al. [30], but not uniformly seen in
other cohorts [31,32].Today KRAS mutation status is
routinely analysed because of its predictive nature in pa-
tients receiving therapeutic antibodies against EGFR,
with treatment restricted to patients with KRAS wild
type tumours [33,34]. In addition to predictive power
with regard to treatment response, the prognostic im-
pact of mutated KRAS has been thoroughly studied in
CRC. In the RASCAL II study, KRAS mutations were
associated with worse prognosis compared to KRAS wild
type in over 3000 patients with CRC, an association that
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ciation to worse prognosis was however restricted to
KRAS 12Gly > Val in stage III disease [31,35]. In the
present study, a similar trend of worse prognosis for
KRAS 12Gly > Val mutated patients was observed. Add-
itional studies have confirmed the association of KRAS
mutations and poor prognosis [30,32,36-38]. Contrary to
these results, two other prospective studies, including
1,404 and 315 patients respectively, did not demonstrate
any major impact of KRAS mutations on prognosis [39,40].
In the present study, the BRAF mutation frequency
(23%) was higher compared to the 5-17% previously re-
ported in colorectal cancer [30,32,41], possibly explained
by the fact that right-sided tumours were predominant
in our cohort and BRAF mutations have been reported to
mainly occur in tumours of the right colon [30,37,39-41].
BRAF mutations were associated with lower likelihood
of tumour dissemination in the whole cohort, as well as
lower likelihood of metastatic recurrence in a separate
analysis of stage II and III tumours. This is in contrast
to a majority of published studies, where BRAF muta-
tions were mostly associated with worse prognosis
[28,30,37,39,40,42,43] or did not exhibit a prognostic
impact [30,38]. Of interest is that two recent studies
showed that BRAF mutations were related to worse
overall survival, but not to relapse-free survival [44,45],
which may be explained by higher frequencies of BRAF
mutations in older individuals [30,45].
BRAF and KRAS mutations were confirmed to be mu-
tually exclusive in this study, as previously reported [46].
BRAF mutations were moreover significantly associated
with MSI, also this in agreement with previous findings
[37,47]. The good prognostic feature of patients with the
MSI tumour type, also seen here, is well-established
[38,48-50] and MSI has been reported to be prognostic
in both stages II and III [48], stage II only [48,50] and
stage III only [19]. As observed by others and similarly
to BRAF mutations, MSI tumours were found to have
larger tumour size, association with lower disease stage
and poor differentiation. However, the frequently seen
associations of MSI with right colon, mucinous tumour
type and female gender was not seen in the present
cohort possibly reflecting the differences in selection
of patients compared with consecutive cohorts. Inter-
estingly, of the patients with left-sided MSI tumours
in the present cohort none developed recurrence. It is
tempting to omit MSI analysis in left-sided colon cancers,
as only about 5% of left-sided tumours are expected to be
MSI, however this study indicates that MSI analysis can as-
sist when selecting patients for adjuvant treatment even for
left sided tumours. We were unable to find any publications
that analysed the prognostic impact of MSI in left-sided
colon cancers, as most studies state that the case number
is too low for meaningful investigations of this subset [38].MSI tumours are characterised by a defective DNA
mismatch repairsystem and the consequential accumula-
tion of mutations in tumour suppressor genes and onco-
genes. Tumours that are MSS commonly exhibit another
type of instability, CIN, with abundant large-scale genomic
alterations that often lead to a higher average DNA copy
number. In contrast to MSI, average DNA copy number is
not routinely assessed. Therefore, in the present study,
average DNA copy number was determined based on
genome-wide SNP array analysis. A low average DNA
copy number was associated with the presence of BRAF
mutation and MSI, but no association with tumour dis-
semination nor disease recurrence was found, suggesting
that the analysis of average DNA copy number would not
improve routine diagnostics.
In addition to KRAS and BRAF mutations, it has
been put forward that mutations in PIK3CA, the p110α
catalytic subunit of phosphatidylinositol-4,5-bisphospho-
nate 3-kinase (PI3K) and a main player in the PI3K/AKT/
mTOR pathway, might be of clinical relevance. Coexist-
ence of PIK3CA exon 9 and 20 mutations has, mainly by
one group, revealed worse prognosis in CRC [22,51]. The
present study revealed that PIK3CA mutations were more
common in MSI and BRAF mutated tumours. However,
no significant association with tumour dissemination was
observed, an observation supported by others [30].
Molecular analysis methods to detect the presence of
mutations and chromosomal or microsatellite instability
are unlikely to replace conventional pathological ana-
lysis, but can potentially help oncologists decide whether
or not colon cancer patients should receive chemother-
apy as an adjuvant treatment to reduce the risk of meta-
static recurrence.
Conclusions
The present study revealed that tumour dissemination is
less likely to occur in colon cancer patients displaying
MSI or BRAF mutation, whereas the presence of a KRAS
mutation increases the likelihood of disseminated disease.
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